Abstract
Patient engagement in research and clinical trials has evolved over time. Patients are no longer simply passive research subjects but are increasingly being integrated into research teams and protocol review teams to help design, implement, and disseminate clinical trial findings. While potential barriers exist for meaningful patient engagement, mechanisms and methods to effectively engage patients and advocacy groups are evolving, and resources and best practices are continually being developed to assist researchers and patients. Additionally, legislation and regulatory guidance are being instituted to promote patient engagement and ensure it is a routine process for clinical trial development. Developing patient-centered clinical trial designs has led to development of innovative clinical trial infrastructures and statistical methods. Patient advocates and organizations are also increasingly developing their own data sources and clinical trials, which represent unique opportunities for researchers to partner with patient groups to rapidly advance drug development.
This is a preview of subscription content, log in via an institution.
References
Anderson M, McCleary KK (2016) On the path to a science of patient input. Sci Transl Med 8:1–6. https://doi.org/10.1126/scitranslmed.aaf6730
Bakkar N, Kovalik T, Lorenzini I et al (2018) Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis. Acta Neuropathol 135:227–247. https://doi.org/10.1007/s00401-017-1785-8
Bombak AE, Hanson HM (2017) A critical discussion of patient engagement in research. J Patient Cent Res Rev 4:39–41. https://doi.org/10.17294/2330-0698.1273
Bottomley A, Pe M, Sloan J et al (2018) Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clin Trials 15:624–630. https://doi.org/10.1177/1740774518795637
Chhatre S, Jefferson A, Cook R et al (2018) Patient-centered recruitment and retention for a randomized controlled study. Trials 19:205. https://doi.org/10.1186/s13063-018-2578-7
Comis RL, Miller JD, Aldigé CR et al (2003) Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21:830–835. https://doi.org/10.1200/JCO.2003.02.105
Davis K, Schoenbaum SC, Audet AM (2005) A 2020 vision of patient-centered primary care. J Gen Intern Med 20:953–957. https://doi.org/10.1111/j.1525-1497.2005.0178.x
Domecq JP, Prutsky G, Elraiyah T et al (2014) Patient engagement in research: a systematic review. BMC Health Serv Res 14:1–9. https://doi.org/10.1016/j.transproceed.2016.08.016
FDA (2018) FDA voices: perspectives from FDA experts. https://www.fda.gov/newsevents/newsroom/fdavoices/default.htm. Accessed 12 Nov 2018
FDA Fact Sheet: Breakthrough Therapies. https://www.fda.gov/regulatoryinformation/lawsenforcedbyfda/significantamendmentstothefdcact/fdasia/ucm329491.htm. Accessed 12 Nov 2018
FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Food and Drug Administration (US), Silver Spring; Co-published by National Institutes of Health (US), Bethesda
Fergusson D, Monfaredi Z, Pussegoda K et al (2018) The prevalence of patient engagement in published trials: a systematic review. Res Involv Engagem 4:17. https://doi.org/10.1186/s40900-018-0099-x
Hanley B, Truesdale A, King A et al (2001) Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. BMJ 322:519–523
Hearld KR, Hearld LR, Hall AG (2017) Engaging patients as partners in research: factors associated with awareness, interest, and engagement as research partners. SAGE Open Med 5:205031211668670. https://doi.org/10.1534/genetics.107.072090
Helwick C (2018) Beat AML trial seeking to change treatment paradigm. [Internet] The ASCO Post
Hohman R, Shea M, Kozak M et al (2015) Regulatory decision-making meets the real world. Sci Transl Med 7:313fs46. https://doi.org/10.1126/scitranslmed.aad5233
Kaitin K (2013) 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev Impact Rep 15:1–4
Kim J, Singh H, Ayalew K et al (2018) Use of pro measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections. Clin Cancer Res 24:1780–1784. https://doi.org/10.1158/1078-0432.CCR-17-2555
Kluetz PG, O’Connor DJ, Soltys K (2018) Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol 19:e267–e274. https://doi.org/10.1016/S1470-2045(18)30097-4
Kuehn CM (2018) Patient experience data in US Food and Drug Administration (FDA) regulatory decision making: a policy process perspective. Ther Innov Regul Sci 52:661–668. https://doi.org/10.1177/2168479017753390
Manganiello M, Anderson M (2011) Back to basics: HIV/AIDS advocacy as a model for catalyzing change. AIDS 1–29. https://www.fastercures.org/assets/Uploads/PDF/Back2BasicsFinal.pdf
Mullins CD, Vandigo J, Zheng Z, Wicks P (2014) Patient-centeredness in the design of clinical trials. Value Health 17:471–475. https://doi.org/10.1016/j.jval.2014.02.012
PCORI (2018) The value of engagement. https://www.pcori.org/about-us/our-programs/engagement/value-engagement. Accessed 12 Nov 2018
Schwartz L, Woloshin S (2015) FDA and the media: lessons from Tysabri about communicating uncertainty. NAM Perspect 5. https://doi.org/10.31478/201509a
Smith SK, Selig W, Harker M et al (2015) Patient engagement practices in clinical research among patient groups, industry, and academia in the United States: a survey. PLoS One 10:e0140232
Tinetti ME, Basch E (2013) Patients’ responsibility to participate in decision making and research. JAMA 309:2331–2332. https://doi.org/10.1001/jama.2013.5592
TransCelerate (2018) Patient experience. http://www.transceleratebiopharmainc.com/initiatives/patient-experience/. Accessed 12 Nov 2018
Unger JM, Cook E, Tai E, Bleyer A (2016) The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 35:185–198. https://doi.org/10.14694/EDBK_156686
Vroom E (2012) Is more involvement needed in the clinical trial design & endpoints? Orphanet J Rare Dis 7:A38. https://doi.org/10.1186/1750-1172-7-S2-A38
Woodcock J, LaVange LM (2017) Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 377:62–70. https://doi.org/10.1056/NEJMra1510062
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Sigal, E., Stewart, M., Merino, D. (2020). Advocacy and Patient Involvement in Clinical Trials. In: Piantadosi, S., Meinert, C. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_57-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52677-5_57-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52677-5
Online ISBN: 978-3-319-52677-5
eBook Packages: Springer Reference MathematicsReference Module Computer Science and Engineering